As filed with the Securities and Exchange Commission on December 27, 2023
Registration No. 333-254600
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO:
FORM S-4 REGISTRATION STATEMENT NO. 333-254600
UNDER
THE
SECURITIES ACT OF 1933
POINT BIOPHARMA GLOBAL INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| Delaware |
|
6770 |
|
85-0800493 |
| (State or other jurisdiction
of incorporation or organization) |
|
(Primary Standard Industrial
Classification Code Number) |
|
(I.R.S. Employer
Identification No.) |
4850 West 78th Street,
Indianapolis, IN 46268
(317) 543-9957
(Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)
Philip L. Johnson
President
Point
Biopharma Global Inc.
Lilly Corporate Center
Indianapolis, Indiana 46285
Telephone: (317) 276-2000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Sophia Hudson, P.C.
Asher Qazi
Kirkland & Ellis LLP
601 Lexington Avenue
New
York, New York 10022
Telephone: (212) 446-4800
Approximate date of commencement of proposed sale to the public: Not Applicable
If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General
Instruction G, check the following box. ☐
If this Form is filed to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated
filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
| Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
| Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
| Emerging growth company |
|
☒ |
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction:
| ☐ |
Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
|
| ☐ |
Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)
|